BOARD OF DIRECTORS
H. Christian Fibiger, PhD – Independent Director
Dr. Fibiger has held senior positions in biotechnology and pharmaceutical companies. Prior to serving as SVP and Chief Scientific Officer at Biovail, he was VP and Global Head of Neuroscience at Amgen, and VP of Neuroscience Discovery and Clinical Investigation at Eli Lilly and Company. Until 1998, he was Professor and Head of the Division of Neurological Sciences at the University of British Columbia. Dr. Fibiger received his PhD in Psychopharmacology from Princeton University.
Mario Saltarelli, M.D., Ph.D. – Chief Executive Officer / Chief Medical Officer
Dr. Saltarelli has over 25 years of experience in the biopharmaceutical industry, primarily in senior executive roles with extensive experience in anxiety, depression and other CNS disorders, and has led companies through all aspects of clinical development, regulatory approvals, strategic planning and major capital raises and mergers & acquisitions. Dr. Saltarelli was formerly with several market-leading companies including Pfizer, Abbott (AbbVie), Annexon, and Syntimmune.
Dr. Saltarelli earned his bachelor of science degree in psychology from the University of Illinois at Urbana-Champaign, a doctor of medicine degree and a doctor of philosophy degree in neuropharmacology from The Johns Hopkins University School of Medicine. He was an intern in internal medicine at the University of Maryland Medical Center and completed neurology residency at The Johns Hopkins Hospital.
Jarett Schultz – Director
Jarett is Vice President, Securities and Disclosure Counsel at atai Life Sciences. He has over 20 years of professional experience in corporate law, including advising boards and management teams of biotechnology companies. Jarett also spent over ten years as Executive Director, Head of Firm Financing and Disclosure in the Legal and Compliance Division at Morgan Stanley where he was responsible for advising on global financing activities, SEC disclosure, Investor Relations and various corporate governance matters.
Jarett is an attorney admitted to the bar of New York and holds a B.A. in English and concentration in Business from Indiana University – Bloomington, and a J.D. from New York Law.
Richard G Farrell – Chief Financial Officer & Chief Operating Officer
Richard is a former Investment Banker with over 23 years of experience in finance, M&A, capital raises and corporate restructures in Australia and the United States. Richard has been founder and CFO of several companies and was formerly an Investment Banker with Beerworth & Partners in Sydney Australia, where he advised on takeovers and private placements. Prior to that, Richard was with Ernst & Young Corporate Finance and formerly Deloitte Touché Corporate Finance. Richard has a BComm. (Australian National University), LLB (Australian National University) and a Graduate Diploma in Finance & Investment (Finsia).
Ryan Barrett – Director
Ryan is the General Counsel at atai Life Sciences. Ryan has spent the majority of the past decade serving on the executive teams of public and private biotechnology companies, for which he has been responsible for building and leading the legal, corporate development, and intellectual property functions. Ryan is also experienced in public and private financings, including IPOs. Over the course of his career, Ryan has held multiple strategic and operational roles within various biotechnology, not-for-profit and financial services companies. Ryan serves as Chairman of the Board.
Ryan is an attorney admitted to the bar of the Commonwealth of Massachusetts; he holds a B.S. in biochemistry and a B.A. in Italian language from Trinity College (Hartford, CT), and a J.D. from Case Western Reserve University School of Law (Cleveland, OH).